Query Drug：Tirzepatide
Query Time：2025-05-29 16:35:52
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
About the Drug
Tirzepatide (Zepbound brand) is used for weight loss, to help lose weight and keep weight off. Tirzepatide works for weight loss by decreasing appetite and slowing the movement of food from the stomach into the small intestine, which may make you feel full more quickly and for a longer period. The Zepbound brand of tirzepatide is also used for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Tirzepatide is a once-weekly injection given under the skin using a pen (autoinjector).
Zepbound (tirzepatide) is FDA-approved for weight loss in adults with obesity or who are overweight and have weight-related medical problems or OSA. Zepbound helps you to lose weight and maintain weight loss and should be combined with diet and exercise.
Tirzepatide (Mounjaro brand) is used for type 2 diabetes to help improve blood sugar levels. In type 2 diabetes, tirzepatide decreases blood sugar levels by helping release insulin when blood sugar levels are high, lowering the amount of sugar the liver makes, and slowing food movement through the intestines. Mounjaro should be used together with diet and exercise.
Mounjaro (tirzepatide) is FDA-approved to treat adults with type 2 diabetes and should be used together with diet and exercise. It can be used as a single therapy (on its own) or with other diabetes medicines, including sulfonylureas, SGLT2 inhibitors, or metformin.
It is not known if tirzepatide can be used in people who have had pancreatitis. Tirzepatide should not be used in people who have type 1 diabetes.
Mounjaro and Zepbound both contain the same active ingredient, tirzepatide, and are made by Eli Lilly and Company. They are both available as single-dose pens in the same strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL, and Zepbound is available as single-dose vials 2.5 mg/0.5 mL and 5 mg/0.5 mL.
Normally, when we eat, natural hormones called GIP and GLP-1 are released by the gut. These hormones increase insulin release, suppress appetite, slow gastric emptying, and increase the feeling of fullness. Tirzepatide works like our natural hormones GIP and GLP-1 by activating the GIP and GLP-1 receptors.
Tirzepatide is a GIP and GLP-1 receptor agonist.
Tirzepatide works (mechanism of action) by activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Patients on tirzepatide (Zepbound) 15mg weekly lost 23.6 kg (52.0 lb) on average after 72 weeks. For patients on the tirzepatide 10mg weekly dose, the average weight loss was 22.2 kg (48.9 lb), and for the tirzepatide 5mg weekly dose, patients lost 16.1 kg (35.5 lb) after 72 weeks. Patients who used a placebo lost 2.4 kg (5.3 lb) over the 72 weeks. These results are from the clinical trial SURMOUNT-1, NCT04184622. Individual results may vary.
The latest clinical trial, SURMOUNT-5 (NCT05822830), demonstrated that tirzepatide (Zepbound) delivered significantly greater weight loss results compared to semaglutide (Wegovy) in a head-to-head trial over a 72-week treatment period at their maximum tolerated doses.
Related Diseases
Extra Information on Drug and Diseases
Drug tirzepatide
RXCUI: 2601723
May Treat
May Diagnose
Similar Drugs
[may_treat] Diabetes Mellitus, Type 2
Source MEDRT
tolazamide
tolbutamide
linagliptin
alogliptin
canagliflozin
pramlintide
colesevelam
lixisenatide
dapagliflozin
albiglutide
empagliflozin
dulaglutide
acarbose
insulin degludec
acetohexamide
insulin, regular, pork
ultralente insulin, human
insulin, regular, beef-pork
insulin, protamine zinc, beef
insulin, protamine zinc, pork
lente insulin, beef
ultralente insulin, beef-pork
ultralente insulin, beef
insulin, prompt zinc, beef-pork
insulin, prompt zinc, beef
insulin, prompt zinc, pork
chlorpropamide
insulin, regular, human
glimepiride
tirzepatide
nateglinide
insulin glargine
miglitol
lente insulin, beef-pork
lente insulin, human
insulin lispro protamine, human
insulin, protamine zinc, beef-pork
insulin, regular, beef
pioglitazone
insulin aspart protamine, human
insulin glulisine, human
glyburide
glipizide
insulin aspart, human
sitagliptin
exenatide
metformin
troglitazone
repaglinide
rosiglitazone
saxagliptin
insulin lispro
lente insulin, pork
[Mechanism of Action] G-Protein-linked Receptor Interactions
Source DAILYMED
[Mechanism of Action] G-Protein-linked Receptor Interactions
Source FDASPL
[Mechanism of Action] Glucagon-like Peptide-1 (GLP-1) Receptor Interactions
Source MEDRT
[Mechanism of Action] Glucagon-like Peptide-1 (GLP-1) Agonists
Source DAILYMED
[Mechanism of Action] Glucagon-like Peptide-1 (GLP-1) Agonists
Source MEDRT
[Mechanism of Action] Glucagon-like Peptide-1 (GLP-1) Agonists
Source FDASPL
[Phamacological Category] GLP-1 Receptor Agonist
Source FDASPL
[Phamacological Category] GLP-1 Receptor Agonist
Source DAILYMED
[Phamacological Category] Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Source FDASPL
[Phamacological Category] Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Source DAILYMED
Orange Book
[Last update] 2024-12-25
Labelers
Tirzepatide's Innovator is ELI LILLY AND CO
Drug Products
The unique dosage forms from the innovator include：1. SOLUTION;SUBCUTANEOUS.
| Index | Route | Brand Name | Labeler | Approval Date | Dosage |
| 1 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 2.5MG/0.5ML (2.5MG/0.5ML) |
| 2 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 15MG/0.5ML (15MG/0.5ML) |
| 3 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 15MG/0.5ML (15MG/0.5ML) |
| 4 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 10MG/0.5ML (10MG/0.5ML) |
| 5 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 10MG/0.5ML (10MG/0.5ML) |
| 6 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 7.5MG/0.5ML (7.5MG/0.5ML) |
| 7 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 7.5MG/0.5ML (7.5MG/0.5ML) |
| 8 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 12.5MG/0.5ML (12.5MG/0.5ML) |
| 9 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 12.5MG/0.5ML (12.5MG/0.5ML) |
| 10 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 5MG/0.5ML (5MG/0.5ML) |
| 11 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 10MG/0.5ML (10MG/0.5ML) |
| 12 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 2.5MG/0.5ML (2.5MG/0.5ML) |
| 13 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 2.5MG/0.5ML (2.5MG/0.5ML) |
| 14 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 7.5MG/0.5ML (7.5MG/0.5ML) |
| 15 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 15MG/0.5ML (15MG/0.5ML) |
| 16 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 15MG/0.5ML (15MG/0.5ML) |
| 17 | SOLUTION;SUBCUTANEOUS | ZEPBOUND (AUTOINJECTOR) | ELI LILLY AND CO | Nov 8, 2023 | 12.5MG/0.5ML (12.5MG/0.5ML) |
| 18 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 5MG/0.5ML (5MG/0.5ML) |
| 19 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 10MG/0.5ML (10MG/0.5ML) |
| 20 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 5MG/0.5ML (5MG/0.5ML) |
| 21 | SOLUTION;SUBCUTANEOUS | MOUNJARO (AUTOINJECTOR) | ELI LILLY AND CO | May 13, 2022 | 12.5MG/0.5ML (12.5MG/0.5ML) |
| 22 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 7.5MG/0.5ML (7.5MG/0.5ML) |
| 23 | SOLUTION;SUBCUTANEOUS | ZEPBOUND | ELI LILLY AND CO | Mar 28, 2024 | 2.5MG/0.5ML (2.5MG/0.5ML) |
| 24 | SOLUTION;SUBCUTANEOUS | MOUNJARO | ELI LILLY AND CO | Jul 28, 2023 | 5MG/0.5ML (5MG/0.5ML) |
Drug Patents
This drug still has 3 effective patents.
| Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
| 9474780 | Jun 9, 2022 | Jan 5, 2036 | Y | Y |
| 11357820 | Jun 30, 2022 | Jun 14, 2039 |
| Y |
| 11918623 | Mar 28, 2024 | Jun 14, 2039 |
|
|
Related Company's Product Pipelines
The innovator ELI LILLY AND CO's portolio contains products with the following 42 API(s)： PENICILLIN V POTASSIUM, CALCIUM GLUCEPTATE, FLURANDRENOLIDE; NEOMYCIN SULFATE, SELPERCATINIB, CEPHALOGLYCIN, ATOMOXETINE HYDROCHLORIDE, CYANOCOBALAMIN, HISTAMINE PHOSPHATE, FLUOXETINE HYDROCHLORIDE; OLANZAPINE, TOBRAMYCIN SULFATE, DULOXETINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE, CEFUROXIME SODIUM, CEFACLOR, ERYTHROMYCIN ESTOLATE, CEFAMANDOLE NAFATE, VITAMIN A PALMITATE, PROCAINE MERETHOXYLLINE; THEOPHYLLINE, GLUCAGON, NORTRIPTYLINE HYDROCHLORIDE, DROMOSTANOLONE PROPIONATE, ERGOCALCIFEROL, GEMCITABINE HYDROCHLORIDE, CEFAZOLIN SODIUM, BETAZOLE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE, QUINIDINE SULFATE, VINCRISTINE SULFATE, DIGITOXIN, DICUMAROL, HEPARIN SODIUM, MENADIOL SODIUM DIPHOSPHATE, PENICILLIN G PROCAINE, MOXALACTAM DISODIUM, GLUCAGON HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE, AMPICILLIN SODIUM, DOBUTAMINE HYDROCHLORIDE, CEPHALOTHIN SODIUM, METOCURINE IODIDE, CINOXACIN, PENICILLIN V
The above products are related to 300 diseases： Gram-Positive Bacterial Infections, Sepsis, Urinary Tract Infections, Escherichia coli Infections, Anthrax, Skin Diseases, Bacterial, Meningococcal Infections, Tetanus, Diphtheria, Botulism, Bacterial Infections, Gonorrhea, Pneumococcal Infections, Actinomycosis, Sinusitis, Salmonella Infections, Pasteurella Infections, Meningitis, Meningococcal, Spirochaetales Infections, Otitis Media, Rheumatic Fever, Staphylococcal Infections, Tetany, Osteoporosis, Esophagitis, Peptic, Gastrointestinal Hemorrhage, Osteoporosis, Postmenopausal, Stomach Ulcer, Heartburn, Heart Arrest, Duodenal Ulcer, Gastroesophageal Reflux, Kidney Failure, Chronic, Drug-Related Side Effects and Adverse Reactions, Dyspepsia, Leg Dermatoses, Inflammation, Foot Dermatoses, Hand Dermatoses, Facial Dermatoses, Bacterial Infections, Escherichia coli Infections, Skin Diseases, Bacterial, Hepatic Encephalopathy, Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung, Attention Deficit Disorder with Hyperactivity, Rhinitis, Allergic, Seasonal, Urticaria, Panic Disorder, Depressive Disorder, Major, Bulimia, Obsessive-Compulsive Disorder, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Intraabdominal Infections, Central Nervous System Infections, Sepsis, Urinary Tract Infections, Respiratory Tract Infections, Skin Diseases, Infectious, Pseudomonas Infections, Staphylococcal Infections, Eye Infections, Bacterial, Bone Diseases, Infectious, Anxiety Disorders, Depressive Disorder, Major, Musculoskeletal Pain, Diabetic Neuropathies, Seizures, Drug-Related Side Effects and Adverse Reactions, Vitamin B 6 Deficiency, Lyme Disease, Escherichia coli Infections, Gonorrhea, Sepsis, Pneumonia, Bacterial, Sinusitis, Pharyngitis, Urinary Tract Infections, Haemophilus Infections, Proteus Infections, Klebsiella Infections, Meningitis, Bacterial, Surgical Wound Infection, Impetigo, Bone Diseases, Infectious, Soft Tissue Infections, Streptococcal Infections, Escherichia coli Infections, Pneumonia, Bacterial, Pharyngitis, Bronchitis, Haemophilus Infections, Otitis Media, Urinary Tract Infections, Proteus Infections, Klebsiella Infections, Skin Diseases, Bacterial, Staphylococcal Infections, Soft Tissue Infections, Bone Diseases, Infectious, Streptococcal Infections, Gonorrhea, Urethritis, Campylobacter Infections, Erythrasma, Whooping Cough, Chlamydia Infections, Syphilis, Gastroenteritis, Staphylococcal Infections, Mycoplasma Infections, Chancroid, Acne Vulgaris, Legionnaires' Disease, Eye Infections, Bacterial, Streptococcal Infections, Escherichia coli Infections, Pneumonia, Bacterial, Urinary Tract Infections, Haemophilus Infections, Proteus Infections, Klebsiella Infections, Skin Diseases, Bacterial, Staphylococcal Infections, Surgical Wound Infection, Bone Diseases, Infectious, Soft Tissue Infections, Photosensitivity Disorders, Night Blindness, Malabsorption Syndromes, Dermatitis, Vitamin A Deficiency, Xerophthalmia, Pulmonary Emphysema, Asthma, Bronchitis, Bronchial Spasm, Bradycardia, Apnea, Shock, Cardiogenic, Gastrointestinal Diseases, Hypotension, Bradycardia, Hypoglycemia, Anaphylaxis, Depressive Disorder, Pain, Enuresis, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Rickets, Osteoporosis, Hypoparathyroidism, Hypophosphatemia, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Breast Neoplasms, Carcinoma, Pancreatic Ductal, Streptococcal Infections, Escherichia coli Infections, Endocarditis, Bacterial, Urinary Tract Infections, Proteus Infections, Klebsiella Infections, Skin Diseases, Bacterial, Staphylococcal Infections, Surgical Wound Infection, Bites, Human, Pneumonia, Bacterial, Soft Tissue Infections, Pellagra, Alcoholic Neuropathy, Beriberi, Thiamine Deficiency, Wernicke Encephalopathy, Atrial Flutter, Malaria, Falciparum, Atrial Fibrillation, Tachycardia, Supraventricular, Tachycardia, Ventricular, Lymphoma, Non-Hodgkin, Wilms Tumor, Neuroblastoma, Leukemia, Rhabdomyosarcoma, Hodgkin Disease, Shock, Cardiogenic, Cardiac Output, Low, Atrial Flutter, Anxiety Disorders, Tachycardia, Supraventricular, Heart Failure, Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism, Thromboembolism, Cerebral Infarction, Venous Thrombosis, Postoperative Complications, Pulmonary Embolism, Thromboembolism, Myocardial Infarction, Coronary Thrombosis, Thrombophlebitis, Angina, Unstable, Sepsis, Urinary Tract Infections, Listeriosis, Syphilis, Escherichia coli Infections, Anthrax, Erysipelothrix Infections, Skin Diseases, Bacterial, Meningococcal Infections, Tetanus, Endocarditis, Diphtheria, Botulism, Bacterial Infections, Gonorrhea, Pneumococcal Infections, Actinomycosis, Salmonella Infections, Pasteurella Infections, Rat-Bite Fever, Endocarditis, Subacute Bacterial, Empyema, Respiratory Tract Infections, Staphylococcal Infections, Pericarditis, Shock, Cardiogenic, Gastrointestinal Diseases, Hypotension, Bradycardia, Hypoglycemia, Anaphylaxis, Panic Disorder, Depressive Disorder, Major, Bulimia, Obsessive-Compulsive Disorder, Urinary Tract Infections, Haemophilus Infections, Pregnancy Complications, Infectious, Listeriosis, Bites, Human, Escherichia coli Infections, Endocarditis, Bacterial, Dysentery, Bacillary, Skin Diseases, Bacterial, Meningococcal Infections, Gonorrhea, Pneumococcal Infections, Actinomycosis, Salmonella Infections, Meningitis, Bacterial, Soft Tissue Infections, Respiratory Tract Infections, Klebsiella Infections, Staphylococcal Infections, Surgical Wound Infection, Cardiac Output, Low, Streptococcal Infections, Escherichia coli Infections, Urinary Tract Infections, Respiratory Tract Infections, Proteus Infections, Klebsiella Infections, Skin Diseases, Bacterial, Staphylococcal Infections, Soft Tissue Infections, Tetanus, Klebsiella Infections, Urinary Tract Infections, Escherichia coli Infections, Proteus Infections, Gram-Positive Bacterial Infections, Sepsis, Urinary Tract Infections, Escherichia coli Infections, Anthrax, Skin Diseases, Bacterial, Meningococcal Infections, Tetanus, Diphtheria, Botulism, Bacterial Infections, Gonorrhea, Pneumococcal Infections, Actinomycosis, Sinusitis, Salmonella Infections, Pasteurella Infections, Meningitis, Meningococcal, Spirochaetales Infections, Otitis Media, Rheumatic Fever, Staphylococcal Infections
